Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes
Status:
Not yet recruiting
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
This phase I/II open-label, dose-finding, multi-center study will assess safety and primary
efficacy of Onureg and Venetoclax combination, to define the optimal biological dose and
optimal treatment duration of Onureg to be used along with Venetoclax for further studies in
previously untreated patients with higher-risk myelodysplastic syndromes (HR-MDS) not
eligible to transplant.